In Win For Barr, Court Denies Tamoxifen Rehearing

Law360, New York (September 18, 2006, 12:00 AM EDT) -- Marking a victory for Barr Pharmaceuticals Inc. in a long-running case over authorized generics, the U.S. Court of Appeals for the Second Circuit has denied a bid for rehearing by a group of consumers in the Tamoxifen Citrate antitrust lawsuits.

Barr, the defendant in the class actions, along with AstraZeneca Pharmaceuticals, said on Monday that the plaintiffs' petitions for rehearing and rehearing en banc were denied on Sept. 15, ending the litigation before the Second Circuit.

"The court's denial of the rehearing petitions re-enforces the growing...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.